I hope you all found some time to relax and recharge your batteries during these exceptionally warm summer months.
Normally, July and August are quieter months which is why we have followed the tradition of previous years of combining news from these two months in one summer edition.
Looking at this Alzheimer Europe newsletter though, I am struck at the variety of news which we have been able to cover with science developments being top of the agenda.
We have dedicated a special section to the Alzheimer's Association International Conference (AAIC) in Chicago in this newsletter and cover some of the key research developments which were presented. This includes the preliminary findings of the SPRINT MIND study about the important effect of intensive blood pressure control on the incidence of MCI and the positive top line results from the Phase II trial of BAN2401.
This newsletter is also full of updates of the many EU funded research projects which Alzheimer Europe is involved in and you can find out more about projects such as AMYPAD, EMIF, EPAD, INDUCT, MinD, MOPEAD, PARADIGM, ROADMAP and SyDAD.
Other interesting developments covered in this newsletter are Portugal adopting a new law on legal capacity, the Alzheimer Europe meeting on intercultural care and support and the announcement by Bill Gates to support AD research with USD 30 million.
I hope you enjoy reading our newsletter packed with news from our members and research updates.
Microsoft co-founder and billionaire philanthropist Bill Gates announced he was investing in the launch of the Diagnostics Accelerator - a "venture philanthropy" fund backed by Bill Gates and Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder.
The Portuguese Parliament approved a new important law. This law is an initiative of the Government with the special involvement of the Minister of Justice. Inspired by the German “Betreuungsgesetz”, the law abolishes “incapacitation” and replaces it with a more flexible legal framework promoting autonomy.
Researchers reported preliminary results from the Systolic Blood Pressure Intervention Trial (SPRINT) Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study at the Alzheimer’s Association International Conference (AAIC). The study showed that intensive blood pressure control led to a significant reduction of new cases of MCI.
After announcing positive topline results on 5 July from their Phase II clinical trial with BAN2401, Eisai and Biogen reported additional results of the secondary outcomes at the AAIC Conference in Chicago on 25 July.
The expert working group addressing intercultural care and support for people with dementia from minority ethnic groups met in Amsterdam on 22 August 2018 to discuss the first draft of the planned report and the development of the tool to collect information on good practices across Europe.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.